Dr. Rafael Arroyo González
Quirónsalud Madrid University Hospital
Ruber Juan Bravo
General Information
Doctor Rafael Arroyo is the Head of the Neurology Department at the Quirónsalud Madrid University Hospital, at the Ruber Juan Bravo University Hospital and the Olympia Medical-Surgical Center. Under his management 40 professionals (neurologists, neurophysiologists, neuropaediatricians, cognitive neuropsychologists, nurses and research coordinators) carry out their medical and research work.
Doctor Arroyo is a Professor of Neurology at the Faculty of Biomedical and Health Sciences, European University of Madrid. He is a national and international expert in neuroimmunological and neurodegenerative diseases (specifically multiple sclerosis, Alzheimer’s, Parkinson’s and strokes).
DegreeDegree and a PhD in Medicine, Complutense University of Madrid, having obtained the Extraordinary Prize for his Doctoral Thesis (UCM 2004): Study of the association of human herpesvirus 6 as an environmental factor implicated in multiple sclerosis.
Master’s in Medical Management and Governance, Spanish National University for Distance Education (UNED 2006).
Research and teaching
Research:
As a researcher, he has been Principal Investigator of 100 national and international clinical trials. 7 FIS research projects of the Carlos III Health Institute (the last 5 as Principal Investigator). 10 private foundation projects obtained in competitive calls (7 as Principal Investigator).
MAIN RESEARCH FINDINGS
ONGOING CLINICAL TRIALS
Multiple sclerosis
A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients. Protocol COMB157G2102. Start year: 2019. Ongoing. PI Rafael Arroyo.
Multicentric, open, single-arm study, before and after change, to evaluate the efficacy, safety and tolerability of alemtuzumab in pediatric patients with RRMS. IMPLEMENTING CENTER: Hospital Universitario Quirónsalud Madrid. PI Rafael Arroyo.
An open- label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease- modifying treatment. Start year: 2016. Ongoing. PI Rafael Arroyo.
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab administered subcutaneously versus teriflunomide administered orally in patients with relapsing forms of multiple sclerosis. Start year: 2016. Ongoing. PI Rafael Arroyo.
Effect of MD1003 (Biotina) in progressive multiple sclerosis: a randomized double blind placebo controlled study. Start year: 2017. Ongoing. PI Rafael Arroyo.
A 2-year Prospective Study to Assess Health-related quality of Life in subjects with Highly-ActiveRelapsing Multiple Sclerosis Treated with Mavenclad (Cladribine). Start year: 2018. Ongoing. PI Rafael Arroyo.
Phase III study: "UbLiTuximab In Multiple Sclerosis Treatment Effects". Start year: 2018. Ongoing. PI Rafael Arroyo.
Alzheimer's disease
Randomised, double-blind, placebo-controlled, two-cohort, parallel-group study to assess the efficacy of CAD106 and CNP520 in participants at risk of developing clinical symptoms of Alzheimer’s disease (AD). Generation 1. CAPI015A2201J. Start 2018. PI Rafael Arroyo.
Randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of CNP520 in participants at risk of developing clinical symptoms of Alzheimer’s disease (AD) Generation 2. CCNP520A2202J. Inicio 2018 ongoing. IP Rafael Arroyo.
A Phase II, Multicenter, Randomized, Parallel Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects with Mild Cognitive Impairment due to Alzheimer’s Disease and Mild Alzheimer’s Dementia to Evaluate the Safety of Continued Dosing in Subjects with Asymptomatic Amyloid-Related Imaging Abnormalities. Aducanumab Study 221AD205. Start year: 2019. Ongoing. PI Rafael Arroyo.
A Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of gantenerumab in patients with prodromal to mild alzheimer’s disease. Start year: 2018. Ongoing. PI Rafael Arroyo.
A Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of crenezumab in patients with prodromal to mild Alzheimer’s disease. Start year: 2017. Ongoing. PI: Rafael Arroyo.
A placebo-controlled, double-blind, parallel-group, 24-month Study to evaluate the efficacy and safety of E2609 in subjects with early Alzheimer’s disease. Start year: 2017. Ongoing. PI: Rafael Arroyo.
Migraine
A 12 week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140mg AMG 334 (Erenumab)against placebo in adult episodic migraine patients who have failed 2-4 prophylactic treatments. Start year: 2017. Co-Researcher Rafael Arroyo.
A Parallel group, double-blind, randomized, placebo controlled phase 3 Trial to Evaluate the efficacy and safety of ALD403 Administered Intravenously in patients with Chronic Migraine. Start year: 2017. Ongoing. Co-Researcher Rafael Arroyo.
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for theProphylactic Treatment of Migraine in Patients with Inadequate Response to Prior Preventive Treatments. Sponsor Teva. Start year: 2018. Ongoing. Co-Researcher Rafael Arroyo.
ONGOING RESEARCH PROJECTS
REEM (Spanish Network of Multiple Sclerosis). Pathogenesis and therapy of Multiple Sclerosis. Financing Body: Carlos III Health Institute. Subdirectorate-General of networks and cooperative research Centers. RETICS 2016. Project Reference: RD16/0015/0013. Duration: January 2017-December 2021 PI: Dr. Luisa María Villar Guimerans (Network coordinator). Collaborating Investigator, Rafael Arroyo.
Study of EBV, HHV-6A and HHV-6B microRNAs present in exosomes isolated from plasma of multiple sclerosis patients: correlation with disease activity and progression. Financing Body: Ramón Areces Foundation. XVIII National Competition for the Awarding of Grants for Research in Life and Matter Sciences. Participating bodies: Quironsalud Madrid Hospital and San Carlos Clinical Hospital. Duration: 2017-2019. Collaborating Investigator, Rafael Arroyo.
Vitamin D and cognitive impairment in multiple sclerosis. Financing Body: Mutua Madrileña Foundation. Participating bodies: Quironsalud Madrid Hospital and San Carlos Clinical Hospital. Duration: 2017-2019. Collaborating Investigator, Rafael Arroyo.
TEACHING
Tenured Professor of Medicine in the Faculty of Biomedical Sciences at the European University of Madrid and he holds the National Accreditation as Tenured Professor in Health Sciences (granted by ANECA).
Publications
He has written 139 international articles with a total impact factor of 949.917 and 4,552 citations. 38 books and chapters of books with an h index=34 (2018). Of particular note are his publications in the world’s leading research journals such as the New England Journal of Medicine and The Lancet.
MOST RELEVANT INTERNATIONAL PUBLICATIONS
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. PMID: 28002688. Impact Factor 2016: 72.406.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):221-234. PMID: 28002679. Impact Factor 2016: 72.406.
F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double- blind, placebo-controlled trial. Lancet 2016; 387: 1075-84. Impact Factor: 44.002.
Arroyo R, Sempere AP, Ruiz-Beato E, Prefasi D, Carreño A, Roset M, Maurino J. Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. BMJ Open. 2017 Mar 8;7(3):e014433. PMID: 28274968. Impact Factor: 2.369.
Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group. Sodium intake and multiple sclerosis activity and progression in BENEFIT. Ann Neurol. 2017 Jul;82(1):20-29. PMID: 28556498. Impact Factor 2016: 9.890.
Galan V, Casanova I, Alvarez-Lafuente R, Sanchez-Jimenez M, Garcia-Martinez MA, Dominguez-Mozo MI, Arias-Leal AM, Garcia-Montojo M, Arroyo R. Fingolimod use for the treatment of multiple sclerosis in a clinical practice setting in Madrid. Clinical Neuropharmacology 2017; 40: 29-33. Impact Factor: 1.748.
Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016 Sep 6;87(10):978-87. PMID: 27511182. Impact Factor 2016: 8.320.
Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, Wheeler-Kingshott CA, Tozer DJ, MacManus DG, Yousry TA, Goodsell M, Yang M, Zhang R, Viglietta V, Dawson KT; CONFIRM study investigators. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015 Mar 17;84(11):1145-52. PMID: 25681448. Impact Factor 2016: 8.320.
Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, Garcia-Martinez MA, Arias-Leal AM, García-Montojo M, Pérez-Pérez S, Arroyo R, Alvarez-Lafuente R. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort. Eur J Clin Invest. 2017 Feb;47(2):158-166. PMID: 28036121. Impact Factor: 2.714.
Fernandez O, Oterino A, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MM, Garcia-Merino JA, Ramio-Torrenta L, Ginestal R, Meca-Lallana JE, Romero-Pinel L, Munoz D, Oliva-Nacarino P, Calles-Hernandez MC, Izquierdo G, Martinez-Gines ML, Saiz A, Comabella M, Casanova-Estruch B, Brieva L, Arroyo R, Rodriguez-Antiguedad A. Review of the novelties from the 32nd ECTRIMS Congress, 2016, presented at the 9th Post-ECTRIMS Meeting (II). Rev Neurol. 2017 Jul 16;65(2):75-84. PMID: 28675259. Impact Factor: 0.743.
Fernandez O, Rodriguez-Antiguedad A, Olascoaga J, Oreja-Guevara C, Prieto JM, Mendibe-Bilbao MM, Garcia-Merino JA, Ramio-Torrenta L, Ginestal R, Meca-Lallana JE, Romero-Pinel L, Munoz D, Saiz A, Calles-Hernandez MC, Izquierdo G, Villar LM, Oliva-Nacarino P, Arnal-Garcia C, Comabella M, Brieva L, Arroyo R, Montalban X. Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting. Rev Neurol. 2016 Jun 16;62(12):559-69. PMID: 27270678. Impact Factor: 0.743.
Communications and Presentations
Dr. Rafael Arroyo has presented 145 papers at international congresses and 209 at national congresses.
